SCHEMBL26064663

SCHEMBL26064663

CNC1CC(C(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.41
HRH3 Q9Y5N1 1/20 0.38
MAPK1 P28482 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
DGAT1 O75907 1/20 0.34
CHRNB2 P17787 2/20 0.34
CHRNA4 P43681 2/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
EPHX1 P07099 2/20 0.33
CTSK P43235 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26044135 1.00 BTK (0.41) BTKHRH3MAPK1NFKB1NFKB2
SCHEMBL1298062 0.84 HRH3 (0.43) BTKHRH3MAPK1NFKB1NFKB2
SCHEMBL28869786 0.83 BTK (0.41) BTKHRH3MAPK1DGAT1CHRNB2
SCHEMBL30886742 0.82 BTK (0.40) BTKHRH3MAPK1DGAT1CHRNB2
SCHEMBL29908992 0.82 BTK (0.40) BTKHRH3MAPK1DGAT1CHRNB2
SCHEMBL3643983 0.81 CHRNB2 (0.48) BTKHRH3MAPK1DGAT1CHRNB2
SCHEMBL3643987 0.81 CHRNB2 (0.48) BTKHRH3MAPK1DGAT1CHRNB2
SCHEMBL4220147 0.81 CHRNB2 (0.48) BTKHRH3MAPK1DGAT1CHRNB2
SCHEMBL30579733 0.80 BTK (0.58) BTKMAPK1NFKB1NFKB2RELA
SCHEMBL27420041 0.80 BTK (0.39) BTKHRH3MAPK1DGAT1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 BTK 809/4885HRH3 3390/4885MAPK1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.